After Chinese CDMO fails, Cambrex acquires ingredient manufacturer Snapdragon Chemistry

While CDMO Cambrex has been expanding steadily throughout the year, its latest acquisition sees a deeper dive into the active pharmaceutical ingredient game.

The New Jersey-based CDMO has agreed to acquire Snapdragon Chemistry, a producer of chemical services and API manufacturing for biopharma customers. The deal will see Cambrex acquire Snapdragon’s two facilities in Waltham, MA. Cambrex did not disclose the deal amount to Endpoints News.

CEO Tom Loewald emailed Endpoints about the reasoning behind the deal:

Cambrex views Snapdragon Chemistry as an excellent strategic fit; the acquisition will enhance each company’s respective offerings, delivering a comprehensive solution for drug substance development and manufacturing challenges. We believe offering a seamless scale-up option from Snapdragon to one of Cambrex’s larger-scale drug substance facilities will be a distinct advantage for Snapdragon customers, compared to the cost and timeline of transferring their product(s) to a 3rd party CDMO for…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.